RU2649975C2 - Бивалентные ингибиторы ингибиторов белков апоптоза и терапевтические способы их применения - Google Patents

Бивалентные ингибиторы ингибиторов белков апоптоза и терапевтические способы их применения Download PDF

Info

Publication number
RU2649975C2
RU2649975C2 RU2015107552A RU2015107552A RU2649975C2 RU 2649975 C2 RU2649975 C2 RU 2649975C2 RU 2015107552 A RU2015107552 A RU 2015107552A RU 2015107552 A RU2015107552 A RU 2015107552A RU 2649975 C2 RU2649975 C2 RU 2649975C2
Authority
RU
Russia
Prior art keywords
cancer
present
iap
apoptosis
structural formula
Prior art date
Application number
RU2015107552A
Other languages
English (en)
Russian (ru)
Other versions
RU2015107552A (ru
Inventor
Шаомэн Ван
Жун ШЭН
Хайин Сунь
Лю ЛЮ
Цзяньфэн Лу
Донна МАКИЧЕРН
Original Assignee
Дзе Реджентс Оф Дзе Юнивёрсити Оф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Реджентс Оф Дзе Юнивёрсити Оф Мичиган filed Critical Дзе Реджентс Оф Дзе Юнивёрсити Оф Мичиган
Publication of RU2015107552A publication Critical patent/RU2015107552A/ru
Application granted granted Critical
Publication of RU2649975C2 publication Critical patent/RU2649975C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
RU2015107552A 2012-08-23 2013-08-16 Бивалентные ингибиторы ингибиторов белков апоптоза и терапевтические способы их применения RU2649975C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692429P 2012-08-23 2012-08-23
US61/692,429 2012-08-23
PCT/US2013/055384 WO2014031487A1 (en) 2012-08-23 2013-08-16 Bivalent inhibitors of iap proteins and therapeutic methods using the same

Publications (2)

Publication Number Publication Date
RU2015107552A RU2015107552A (ru) 2016-10-10
RU2649975C2 true RU2649975C2 (ru) 2018-04-06

Family

ID=50148520

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015107552A RU2649975C2 (ru) 2012-08-23 2013-08-16 Бивалентные ингибиторы ингибиторов белков апоптоза и терапевтические способы их применения

Country Status (12)

Country Link
US (1) US8883771B2 (enExample)
EP (1) EP2888265B1 (enExample)
JP (1) JP6247298B2 (enExample)
KR (2) KR102111704B1 (enExample)
CN (3) CN109575049B (enExample)
AU (1) AU2013306087B2 (enExample)
CA (1) CA2882496C (enExample)
ES (1) ES2654623T3 (enExample)
HK (1) HK1211030A1 (enExample)
MX (1) MX366130B (enExample)
RU (1) RU2649975C2 (enExample)
WO (1) WO2014031487A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JP2017511348A (ja) * 2014-04-16 2017-04-20 成都大学 Ｂｃｒ−Ａｂｌ二倍体の阻害剤、その調製方法及びその用途
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2017253560B2 (en) 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
JP6953435B2 (ja) * 2016-05-09 2021-10-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二量体化合物
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
GB2567126A (en) * 2017-06-23 2019-04-10 Femtogenix Ltd PBC compounds
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
CA3101835A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
JP2022511437A (ja) 2018-11-26 2022-01-31 デバイオファーム インターナショナル エス．エー． Ｈｉｖ感染の組み合わせ治療
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
US12636370B2 (en) 2019-08-08 2026-05-26 Institute For Cancer Research Combination therapy for treatment of cancer
AU2020356356A1 (en) 2019-09-25 2022-05-12 Debiopharm International S.A. Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
US12678509B2 (en) * 2019-11-08 2026-07-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (IAP) protein antagonists
WO2021098771A1 (en) * 2019-11-19 2021-05-27 Ascentage Pharma (Suzhou) Co., Ltd. Treatment method with iap inhibitor
CN112972684B (zh) * 2019-12-02 2024-05-31 苏州亚盛药业有限公司 Iap抑制剂与parp或mek抑制剂或其他化学治疗剂的组合
CN118542872A (zh) * 2019-12-04 2024-08-27 苏州亚盛药业有限公司 药物组合及其用途
EP4081217A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
WO2021223664A1 (en) * 2020-05-04 2021-11-11 Ascentage Pharma (Suzhou) Co., Ltd. Methods for treating coronavirus infections
TWI794895B (zh) * 2020-07-16 2023-03-01 大陸商蘇州亞盛藥業有限公司 雙二氮雜雙環化合物或其鹽的結晶形式或無定形形式
CN116963732A (zh) * 2021-02-23 2023-10-27 苏州亚盛药业有限公司 药物组合物及其制备方法
JP2024528174A (ja) 2021-08-02 2024-07-26 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド 医薬組合せおよびその使用
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
EP4529455A1 (en) 2022-05-23 2025-04-02 Inhibrx Biosciences, Inc. Dr5 agonist and iap antagonist combination therapy
US12508320B2 (en) 2023-06-29 2025-12-30 SeeCure Taiwan Co., Ltd. Drug conjugate, pharmaceutical composition and method of treating hepatitis
AU2024367811A1 (en) * 2023-10-24 2026-05-07 Tract Pharmaceuticals, Inc. Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19
WO2025261398A1 (en) * 2024-06-19 2025-12-26 Ascentage Pharma (Suzhou) Co., Ltd. Methods for treating diseases caused by hiv infection
CN119100970B (zh) * 2024-08-30 2025-09-30 中国药科大学 基于热休克蛋白90的二价抑制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007130626A2 (en) * 2006-05-05 2007-11-15 The Regents Of The University Of Michigan Bivalent smac mimetics and the uses thereof
RU2342387C2 (ru) * 2003-04-09 2008-12-27 Чоонгвае Фарма Корпорейшн Миметики с обратной конфигурацией и способы их применения

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723122B1 (en) 2004-03-01 2014-11-19 Board of Regents, The University of Texas System Dimeric small molecule potentiators of apoptosis
CN101128425B (zh) * 2005-02-25 2012-12-26 泰特拉洛吉克药业公司 Iap二聚体抑制剂
WO2008128171A2 (en) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
ES2643233T3 (es) * 2009-10-23 2017-11-21 The Regents Of The University Of Michigan Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2342387C2 (ru) * 2003-04-09 2008-12-27 Чоонгвае Фарма Корпорейшн Миметики с обратной конфигурацией и способы их применения
WO2007130626A2 (en) * 2006-05-05 2007-11-15 The Regents Of The University Of Michigan Bivalent smac mimetics and the uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yuefeng Peng; Haiying Sun; Jianfeng Lu; Liu Liu; Qian Cai; Rong Shen; Chao-Yie Yang; Han Yi; Shaomeng Wang, Bivalent Smac Mimetics with a Diazabicyclic Core as Highly Potent Antagonists of XIAP and cIAP1/2 and Novel Anticancer Agents, Journal of Medicinal Chemistry, т. 55, n:1, стр.: 106 - 114, 2012. *

Also Published As

Publication number Publication date
AU2013306087A1 (en) 2015-03-12
US8883771B2 (en) 2014-11-11
CN109575049A (zh) 2019-04-05
CA2882496C (en) 2020-07-14
ES2654623T3 (es) 2018-02-14
KR20200054334A (ko) 2020-05-19
WO2014031487A1 (en) 2014-02-27
CA2882496A1 (en) 2014-02-27
WO2014031487A8 (en) 2014-05-30
JP6247298B2 (ja) 2017-12-13
KR102237888B1 (ko) 2021-04-07
EP2888265B1 (en) 2017-10-11
CN104718209A (zh) 2015-06-17
RU2015107552A (ru) 2016-10-10
CN109485662A (zh) 2019-03-19
HK1211030A1 (en) 2016-05-13
AU2013306087B2 (en) 2017-08-10
MX2015002371A (es) 2015-10-05
CN109485662B (zh) 2021-12-21
MX366130B (es) 2019-06-28
KR20150044937A (ko) 2015-04-27
EP2888265A4 (en) 2016-01-27
EP2888265A1 (en) 2015-07-01
US20140057924A1 (en) 2014-02-27
JP2015528447A (ja) 2015-09-28
KR102111704B1 (ko) 2020-05-15
CN109575049B (zh) 2021-07-30

Similar Documents

Publication Publication Date Title
JP6247298B2 (ja) Ｉａｐタンパク質の二価阻害薬およびそれを用いた治療方法
KR102210316B1 (ko) Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법
KR101762724B1 (ko) Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
EP2373658A2 (en) Stat3 inhibitors and therapeutic methods using the same
KR20200081417A (ko) 아폽토시스 억제제 단백질을 표적화하는 신규 작용제
HK40005133B (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
HK40005133A (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
HK40006375A (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
HK40008278A (en) Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
HK40008279B (en) Medical use of bcl-2/bcl-xl inhibitors and pharmaceutical compositions thereof
HK40008279A (en) Medical use of bcl-2/bcl-xl inhibitors and pharmaceutical compositions thereof
HK40025523A (en) Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer